-
M1a disease, systemic triplet therapy, and de-escalation strategies in HSPC
November 5, 2023The last day of EMUC23 began with Plenary Session 13: New standards and novel approaches in advanced prostate cancer,...
00 -
2023 ends with big game changers for GU cancers
November 4, 2023Chaired by Prof. Axel Merseburger (DE), Prof. Karim Fizazi (FR) and Prof. Valerie Fonteyne (BE), the game-changing session on...
-
Shorter treatment, better imaging for high-risk PCa?
November 3, 2023Co-chaired by Assoc. Prof. Juan Gómez Rivas (ES), Prof. Peter Hoskin (GB), Assoc. Prof. Daniela Oprea-Lager (NL) and Prof....
-
ESUP: A review of biomarkers and molecular tests in bladder urothelial carcinoma
November 2, 2023The Uropathology Symposium of the EAU Section of Uropathology (ESUP) delivered the latest updates on biomarkers and molecular tests...
-
ESUI: Getting ready for the new EU approach to PCa screening
November 2, 2023This year, the annual EAU Section of Urological Imaging (ESUI) meeting has been integrated into the 15th European Multidisciplinary...
-
AI opportunities in GU Cancers
November 12, 2022Looking to the future, Prof. Arnulf Stenzl (DE), Prof. Alberto Briganti (IT) and Dr. Bob Schijvenaars (NL) chaired the...
-
New trial results for PEACE-1, OpeRa, and adjuvant therapies in high-risk RCC
November 12, 2022A selection of new trial results were shared and discussed in Plenary Session 5 on day three of EMUC22....
-
Protect yourself: Fake EMUC22 websites and scam emails
September 8, 2022Planning to attend EMUC22? Protect yourself against registration and hotel booking scams. Here’s how: Register via EMUC22’s official website...
